Quantcast

Latest immunotherapy Stories

2014-07-25 23:03:18

Harvard Neuro-Oncologist presents latest brain tumor research and treatment options at American Brain Tumor Association’s annual conference. Chicago, IL (PRWEB) July 25, 2014 Progress in understanding the molecular genetics of brain tumors has ushered in a new era of promising brain tumor treatments, according to Patrick Wen, MD, professor of neurology, Harvard Medical School, director of the Center for Neuro-Oncology, Dana-Farber Cancer Institute. At the American Brain Tumor...

2014-07-24 16:26:32

OTTAWA, July 24, 2014 The Canadian Society of Allergy and Clinical Immunology (CSACI) would like to comment on the death of Mrs. Lucie Roussel, Mayor of La Prairie, on Sunday. As previously reported, Mrs. Roussel stepped on a wasp nest and was stung multiple times. Unfortunately, the autopsy report is not yet available. It is thought that Mrs. Roussel died from a toxic reaction to the stings which usually requires at least 50 stings, or anaphylaxis which can occur after one sting....

2014-07-24 08:33:56

ThermoDox® Continues to Demonstrate Impressive Local Response Rate in Refractory Patients LAWRENCEVILLE, N.J., July 24, 2014 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN) announced today positive interim data from its ongoing open-label Phase 2 DIGNITY Trial of ThermoDox® in Recurrent Chest Wall Breast Cancer (RCWBC). The trial is designed to enroll 20 patients at several U.S. clinical sites and is evaluating ThermoDox in combination with mild hyperthermia. Of the 13 patients...

2014-07-23 08:32:38

Treatment with VGX-3100 induces regression of precancerous cervical disease and clears HPV infection with robust T cell responses PLYMOUTH MEETING, Pa., July 23, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today announced successful results from its randomized, double-blind, placebo-controlled phase II trial of VGX-3100 in women with biopsy-proven cervical intraepithelial neoplasia 2/3 (CIN2/3) associated with human papillomavirus (HPV) types 16 or 18. Treatment...

2014-07-17 08:25:12

MONMOUTH JUNCTION, N.J., July 17, 2014 /PRNewswire/ -- CytoSorbents Corporation (OTCQB: CTSO), a critical care immunotherapy company commercializing its CytoSorb® cytokine adsorber in multiple countries worldwide, announced the PDF availability of the first publication describing the use of CytoSorb® intra-operatively during cardiac surgery at the Ludwig Maximilian University of Munich Hospital - Grosshadern Campus, in Germany....

2014-07-16 08:27:11

OXFORD, England and INDIANAPOLIS, July 16, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Immunocore Limited today announced they have entered into a co-discovery and co-development collaboration to research and potentially develop novel T cell-based cancer therapies. Using Immunocore's Immune Mobilising Monoclonal T-Cell Receptor Against Cancer (ImmTAC) technology, the companies will seek to use the power of the body's own immune system to attack cancer cells. ImmTACs...

2014-07-16 04:21:39

TUEBINGEN, Germany, July 16, 2014 /PRNewswire/ -- Funds will be used to complete phase 3 study with IMA901 and to invest in the expansion of immatics' Human Immunopeptidome Program to identify the most relevant targets for cancer immunotherapies immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company leading the development of advanced immunotherapies that are active against cancer, today announces that it has...

2014-07-14 16:24:17

- TNIB extends record date pursuant to a demand by shareholders. ORLANDO, Fla., July 14, 2014 /PRNewswire/ -- TNI BioTech, Inc. - (OTCQB: TNIB) ("TNIB" or the "Company"), a biotechnology company focused on developing innovative, targeted immune therapies, today announced that its Board of Directors has extended the record date of our spin-off of Cytocom, Inc., a subsidiary of TNIB. The Company's Board received a Letter on July 13, 2014 from Carricklee Consulting Ltd on behalf of...

2014-07-14 08:26:52

Company Commemorates its Transformative Acquisition of EGEN, Inc. and the Initiation of the Phase III Pivotal OPTIMA Study in Primary Liver Cancer LAWRENCEVILLE, N.J., July 14, 2014 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN), a leading oncology drug development company, announced today that the Company will ring the NASDAQ Stock Market closing bell on Wednesday, July 16, 2014 in Times Square, New York, NY. President and CEO Michael H. Tardugno and members of the Celsion and...

2014-07-10 23:10:54

Tampa Bay Research Institute (TBRI), a well-respected private, non-profit biomedical research institute, announced today that its most recent findings describing how the pine cone extract affects the immune system have been published in the journal, BMC Complementary and Alternative Medicine. (PRWEB) July 10, 2014 Tampa Bay Research Institute (TBRI), a well-respected private, non-profit biomedical research institute, announced today that TBRI's most recent findings describing how the...


Word of the Day
siliqua
  • A Roman unit of weight, 1⁄1728 of a pound.
  • A weight of four grains used in weighing gold and precious stones; a carat.
  • In anatomy, a formation suggesting a husk or pod.
  • The lowest unit in the Roman coinage, the twenty-fourth part of a solidus.
  • A coin of base silver of the Gothic and Lombard kings of Italy.
'Siliqua' comes from a Latin word meaning 'a pod.'
Related